Company intelligence / Profile preview

Ranvier Health

Bristol, England, United Kingdomranvierhealth.com ↗

Ownership: Private
Development stage: Other

Overview

Ranvier Health is developing the Mood Assessment Taste Test (MATT), a novel diagnostic device intended to serve as a surrogate biomarker for depression. The company is currently running clinical trials to validate whether changes in taste sensitivity can predict antidepressant effectiveness and correlate with mood outcomes in patients with major depressive disorder. No published clinical results are available yet, but the main study is actively recruiting participants.

Therapeutic areas: Psychiatry
Modalities: Device (diagnostic test)Non-pharmacological therapy (biomarker-based diagnostic aid)
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Ranvier Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ranvier Health.

Explore the full profile